BioXcel Therapeutics is a drug manufacturers - specialty & generic business based in the US. BioXcel Therapeutics shares (BTAI) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.58 – an increase of 5.33% over the previous week. BioXcel Therapeutics employs 37 staff and has a trailing 12-month revenue of around $752,000.
Become a Finder member, open a SoFi Active Invest account and make a first deposit of $1,000 or more to receive a $150 gift card. Offer ends March 4, 2026.
T&Cs and limits apply.
0588148b-2286-4b8f-9672-9c8cdafc0370-Get up to $1,000 in stock
Get up to $1,000 in stock
Trade stocks, options, ETFs, mutual funds, alternative asset funds
$0 commission on stocks, ETFs and options with no options contract fees
Get up to $1,000 in stock when you open & fund a new Active Invest account.
Probability of Member receiving $1,000 is a probability of 0.026%; If you don’t make a selection in 45 days, you’ll no longerqualify for the promo. Customer must fund their account with a minimum of $50.00 to qualify. Probability percentage is subject to decrease.
Terms and conditions apply*. For 401k rollovers, existing SoFi IRA members must complete 401k rollovers via this link See full terms and For SoFi members without a SoFi IRA, a SoFi IRA must first be opened, and 401k rollover must be completed utilizing Capitalize via this link. SoFi and Capitalize will charge no additional fees to process a 401(k) rollover to a SoFi IRA. SoFi is not liable for any costs incurred from the existing 401k provider for rollover. Please check with your 401k provider for any fees or costs associated with the rollover. For IRA contributions, only deposits made via ACH and cash transfer from SoFi Bank accounts are eligible for the match. Click here for the 1% Match terms and conditions.
Must be a SoFi Plus member at the time a recurring deposit is received into your SoFi Active or Automated investing account to qualify. Bonus calculated on net monthly recurring deposits made via ACH and paid out as Rewards Points. See Rewards Terms of Service. SoFi reserves the right to change or terminate this promotion at any time without notice. See terms and limitations. https://www.sofi.com/sofiplus/invest/#disclaimers
eToro securities trading offered by eToro USA Securities, Inc. (‘the BD”), member of FINRA and SIPC. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. Finder is not an affiliate and may be compensated if you access certain products or services offered by the BD.
d19c0be9-29b6-4644-a071-32c476ff5e24-Top pick for match bonus
Top pick for match bonus
Trade stocks, ETFs, options, futures and bonds all in one place
$0 commissions on stocks, ETFs and equity options, with low contract fees
Deposit or transfer $100,000+ to earn a 4% Match Bonus. Plus: Get a $100 transfer fee reimbursement on your first brokerage transfer of $2,000 or more. T&C apply.
Open an account.Provide your personal information and sign up.
Fund your account.Deposit funds into your account by linking your banking information or transfer funds from another trading account.
Search for the stock name – BTAI.Search for the stock by name or ticker symbol.
Buy the stock. Place your order. It's that simple.
Buy BioXcel Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
BioXcel Therapeutics stock price (NASDAQ: BTAI)
Use our graph to track the performance of BTAI stocks over time.
Is it a good time to buy BioXcel Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
BioXcel Therapeutics price performance over time
Historical closes compared with the close of $1.54 from 2026-02-12
1 week (2026-02-06)
2.67%
1 month (2026-01-14)
-22.61%
3 months (2025-11-14)
-5.52%
6 months (2025-08-14)
-67.58%
1 year (2025-02-14)
-33.33%
2 years (2024-02-14)
-96.90%
3 years (2023-02-14)
520.32
5 years (2021-02-12)
971.2
BioXcel Therapeutics financials
Revenue TTM
$752,000
Gross profit TTM
$-212,000
Return on assets TTM
-67.31%
Return on equity TTM
-1766.94%
Profit margin
0%
Book value
$-4.45
Market Capitalization
$33.7 million
TTM: trailing 12 months
BioXcel Therapeutics share dividends
We're not expecting BioXcel Therapeutics to pay a dividend over the next 12 months.
Have BioXcel Therapeutics's shares ever split?
BioXcel Therapeutics's shares were
split on a 1:16 basis on 9 February 2025
. So if you had owned 16 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your BioXcel Therapeutics shares – just the quantity. However, indirectly, the new 1500% higher share price could have impacted the market appetite for BioXcel Therapeutics shares which in turn could have impacted BioXcel Therapeutics's share price.
BioXcel Therapeutics share price volatility
Over the last 12 months, BioXcel Therapeutics's shares have ranged in value from as little as $1.17 up to $8.08. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioXcel Therapeutics's is 0.2. This would suggest that BioXcel Therapeutics's shares are less volatile than average (for this exchange).
BioXcel Therapeutics overview
BioXcel Therapeutics, Inc. , together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia. The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc.
Frequently asked questions
null What percentage of BioXcel Therapeutics is owned by insiders or institutions? Currently 4.208% of BioXcel Therapeutics shares are held by insiders and 13.271% by institutions.How many people work for BioXcel Therapeutics? Latest data suggests 37 work at BioXcel Therapeutics.When does the fiscal year end for BioXcel Therapeutics? BioXcel Therapeutics's fiscal year ends in December.Where is BioXcel Therapeutics based? BioXcel Therapeutics's address is: 555 Long Wharf Drive, New Haven, CT, United States, 06511What is BioXcel Therapeutics's ISIN number? BioXcel Therapeutics's international securities identification number is: US09075P2048What is BioXcel Therapeutics's CUSIP number? BioXcel Therapeutics's Committee on Uniform Securities Identification Procedures number is: 09075P105
Discover the best stock picking services based on expert analysis, pricing, and strategy fit. Compare top tools to find the right service for your investing style in 2026.
Discover the best robo-advisors of 2026. Compare fees, account minimums and features from top platforms that automate investing for beginners and pros.
Vanguard is an investor-owned company that specializes in low-cost funds, but some fees and features lag the competition.
Advertiser disclosure
Finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which Finder receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. Finder compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
How likely would you be to recommend Finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
